Filing Flows › Gilead Sciences (GILD) › Q1 2025
Gilead Sciences (GILD) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 7, 2025
Gilead Sciences (GILD) reported revenue of $6.7B for the first quarter 2025 (Q1 2025), -0.3% from a year earlier and -12% from the quarter before. Operating margin was 33.6%, net earnings $1.3B (19.7% of revenue).
Gilead Sciences, Q1 2025: revenue $6.7B (-0.3% year over year), operating margin 33.6%, net earnings $1.3B, operating cash flow $1.8B. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $6.7B | -12% | -0.3% |
| Operating profit | $2.2B | -9% | — |
| Net earnings | $1.3B | -26% | — |
| Operating cash flow | $1.8B | -41% | -21% |
| Free cash flow | $1.7B | — | -22% |
What changed
Revenue was $6.7B in Q1 2025, roughly flat year over year and down 12% from the previous quarter. Biktarvy was the largest line at 47% of revenue. Veklury lost $0.25B year over year (down 46%), 1332% of the total change.
Operating profit was $2.2B, a 33.6% margin (up 98.2 points year over year). Total costs fell 60% while revenue was flat. Net earnings were $1.3B. The effective tax rate was 20.3%.
Operating cash flow was $1.8B (down 21% year over year), 134% of net earnings. Non-cash charges added back $0.10B of depreciation and $0.21B of share-based compensation. Working capital and other items added $0.14B. After purchases of property, plant and equipment ($0.10B), free cash flow as the company reports it was $1.7B.
Questions
What was Gilead Sciences' revenue in the first quarter 2025?
Gilead Sciences (GILD) reported revenue of $6.7B for the first quarter 2025 (Q1 2025), -0.3% from a year earlier and -12% from the quarter before.
Was Gilead Sciences profitable in the first quarter 2025?
Operating profit was $2.2B (33.6% of revenue) and net earnings $1.3B.
Source: Gilead Sciences 10-Q on SEC EDGAR.